DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Phase II Randomized Study of Leuprolide Vs Oral Contraceptive Therapy Vs Leuprolide and Oral Contraceptive Therapy for Ovarian Hyperandrogenism

Information source: Office of Rare Diseases (ORD)
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hyperandrogenism

Intervention: leuprolide (Drug); Ethinyl estradiol/norethindrone (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: National Center for Research Resources (NCRR)

Official(s) and/or principal investigator(s):
Karen E. Elkind-Hirsch, Study Chair, Affiliation: Baylor College of Medicine


OBJECTIVES: I. Evaluate the beneficial effects of leuprolide depot, oral contraceptive therapy, and leuprolide/oral contraceptive therapy in the management of patients with ovarian hyperandrogenism.

Clinical Details

Study design: Allocation: Randomized, Primary Purpose: Treatment

Detailed description: PROTOCOL OUTLINE: This is a randomized study. Patients are randomly assigned to a 6-month course of leuprolide versus ethinyl estradiol/norethindrone (Ovcon 35) versus leuprolide plus Ovcon 35. Leuprolide is administered intramuscularly in depot form every 28 days.


Minimum age: 15 Years. Maximum age: 40 Years. Gender(s): Female.


PROTOCOL ENTRY CRITERIA: Disease Characteristics

- Ovarian hyperandrogenism with Lorenzo hirsutism score 7 to 20, with or without severe


- Serum hormone levels: Follicle-stimulating hormone no greater than 40 mIU/mL

Luteinizing hormone no greater than 40 mIU/mL Testosterone 60 to 200 ng/dL Dehydroepiandrosterone sulfate no greater than 430 micrograms/dL 17-hydroxyprogesterone no greater than 3. 3 ng/mL in follicular phase Prolactin no greater than 18 ng/dL

- No adrenal or ovarian tumors

Prior/Concurrent Therapy

- At least 6 months since exogenous steroids At least 48 hours since drugs other than

acetaminophen, ibuprofen, and aspirin Patient Characteristics

- No malignancy, including the following carcinomas: Breast Cervix Ovary Uterus No

other serious illness No cigarette smokers No nursing women No pregnancy within 6 months prior to entry

Locations and Contacts

Additional Information

Starting date: January 1993
Last updated: June 23, 2005

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017